Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8 T Cell Responses

Publication

Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8 T Cell Responses

Journal Paper/Review - Oct 10, 2020

Ring Sandra, Królik Michał Wojciech, Hartmann Fabienne, Schmidt Erika, Ali Omar Hasan, Ludewig Burkhard, Kochanek Stefan, Flatz Lukas

Citation

Ring S, Królik M, Hartmann F, Schmidt E, Ali O, Ludewig B, Kochanek S, Flatz L. Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8 T Cell Responses. Mol Ther Oncolytics 2020; 19:179-187.

Type

Journal Paper/Review (English)

Journal

Mol Ther Oncolytics 2020; 19

Publication Date

Oct 10, 2020

Issn Print

2372-7705

Pages

179-187

Brief description/objective

Cancer vaccination aims at inducing an adaptive immune response against tumor-derived antigens. In this study, we utilize recombinant human adenovirus serotype 5 (rAd5) and recombinant lymphocytic choriomeningitis virus (rLCMV)-based vectors expressing the melanocyte differentiation antigen gp100. In contrast to single or homologous vaccination, a heterologous prime boost vaccination starting with a rAd5-gp100 prime immunization followed by a rLCMV-gp100 boost injection induces a high magnitude of polyfunctional gp100-specific CD8 T cells. Our data indicate that an optimal T cell induction is dependent on the order and interval of the vaccinations. A prophylactic prime boost vaccination with rAd5- and rLCMV-gp100 protects mice from a B16.F10 melanoma challenge. In the therapeutic setting, combination of the vaccination with low-dose cyclophosphamide showed a synergistic effect and significantly delayed tumor growth. Our findings suggest that heterologous viral vector prime boost immunizations can mediate tumor control in a mouse melanoma model.